MIRA Pharmaceuticals' Preclinical Study Shows MIRA-55's Enhanced Efficacy Over THC in Treating Anxiety and Cognitive Decline
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals announced promising preclinical results for its novel oral pharmaceutical marijuana analog, MIRA-55, which showed enhanced efficacy over THC in treating anxiety and cognitive decline. The studies confirmed MIRA-55's higher efficacy at CB1 and CB2 receptors and its potential for more consistent and prolonged therapeutic benefits.
July 15, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals' preclinical study shows that MIRA-55 has higher efficacy than THC in treating anxiety and cognitive decline, confirming its potential for more consistent and prolonged therapeutic benefits.
The preclinical study results confirm MIRA-55's higher efficacy at CB1 and CB2 receptors compared to THC, indicating its potential for stronger and more reliable relief for anxiety and cognitive decline. This positive development is likely to boost investor confidence and positively impact MIRA's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100